摘要
目的观察派罗欣联合利巴韦林治疗慢性丙型肝炎的临床疗效。方法选择慢性丙型肝炎患者40例作为研究对象,随机分为观察组和对照组,每组20例,对照组采用常规治疗方法,观察组采用派罗欣联合利巴韦林治疗,连续使用1年,比较两组治疗效果及患者生活质量情况。结果观察组患者应答率(95.0%)明显高于对照组患者(70.0%),治疗效果差异有统计学意义(P<0.05);治疗后,观察组患者的躯体功能评分(74.17±7.61)分、心理功能(59.31±5.37)分、社会功能(57.83±2.74)分、认知功能(58.84±5.74)分和总体生活质量(81.84±8.34)分明显高于对照组(P<0.05)。结论派罗欣联合利巴韦林治疗慢性丙型肝炎,可以显著提高患者治疗效果及生活质量。
Objective To analyze the curative effect of pegasys combined with ribavirin in the treatment of chronic hepatitis. Methods 40 cases of patients with chronic hepatitis C in our hospital were selected as the objects for this study, these patients were randomly divided into the observation group and the control group, 20 cases in each group, the control group using conventional methods for treatment, and the observation group was treated with Pegasys ribavirin, continuous use of a year. The treatment effect and quality of life of the two groups were compared. Results The patients in the observation group response rate （95.00/6o） was higher than that of the control group of patients （70.0%）, indicating that differences in treatment effect was significant features （P〈0. 05） ; after the treatment, the patients in the observation group body function （74. 17±7.61）, mental function（59.31±5.37）, social function（57.83±2.74）, cognitive function（58.84±5.74） and overall quality of life （81.84±8.34） were significantly higher than those in control group （P 〈0.05 ）. Conclusion Pegasys combined with ribavirin in the treatment of chronic hepatitis C can significantly improve patient＇s outcomes and the quality of life.
出处
《西部医学》
2012年第12期2345-2346,共2页
Medical Journal of West China
